Instruction for use: Proginova

Active substance: Estradiol valerate

ÀÒÕ Code: G03CA03 Estradiol

Pharmacological groups

Estrogens [Estrogens, gestagens; their homologs and antagonists]

Nosological classification (ICD-10)

E28.3 Primary ovarian failure

Hypogonadism of the ovary (primary), Hypofunction of the ovaries, Estrogen deficiency, Insufficient estrogen content in the body, Insufficiency estrogenic, Insufficiency of estrogens, Primary dysfunction of the ovaries, Estrogen-deficient conditions

M81.0 Postmenopausal osteoporosis

Menopause osteoporosis, Osteoporosis in menopause, Osteoporosis in menopause, Osteoporosis in postmenopausal women, Osteoporosis in the postmenopausal period, Postmenopausal osteoporosis, Osteoporosis in postmenopausal women, Perimenopausal osteoporosis, Postmenopausal osteoporosis, Post-menopausal osteoporosis, Postmenopausal osteoporosis, Postmenopausal demineralization of bones, Osteoporosis with estrogen deficiency, Osteoporosis in postmenopausal women, Osteoporosis in postmenopausal women and after hysterectomy

N95.1 menopausal and menopausal status of women

Atrophy of the mucosa of the lower genital tract, caused by Oestrogel deficiency; Vaginal dryness; Autonomic dysfunction in women; gipoOestrogeliya state; Deficiency of Oestrogel in menopausal women; Degenerative changes of the mucous membrane in the menopause; Natural menopause; an intact uterus; climacteric; Menopause women; Menopause in women; menopausal depression; Climacteric ovarian dysfunction; Menopause; Climacteric neurosis; Menopause; Menopausal symptoms complicated psychovegetative; Climacteric syndrome; Climacteric vegetative disorders; Climacteric psychosomatic disorder; menopausal disorders; Menopausal disorders in women; menopausal condition; Climacteric vascular disorders; Menopause; Menopausal vasomotor symptoms; menopausal period; Lack of Oestrogel; Feeling the heat; Pathological menopause; perimenopause; menopause; postmenopausal; Premature menopause; premenopauznom period; tides; hot flashes; flushing in the Meno and postmenopausal; Hot flashes / hot flashes in menopause; Heart attack during menopause; Early menopause in women; Disorders of menopause; climacteric syndrome; Vascular complications of menopause; Physiological menopause; Oestrogeldefitsitnye state; premature Menopause

Composition

Dragee 1 dragee

Estradiol valerate 2 mg

auxiliary substances: lactose monohydrate 46 - 250 mg; cornstarch 26 - 200 mg; Povidone 25,000 - 3 mg; talc - 2.4 mg; magnesium stearate - 0.15 mg; sucrose crystalline 33 - 540 mg; Povidone 700,000 - 0.323 mg; macrogol 6000 - 3.719 mg; calcium carbonate precipitated 14 - 572 mg; talc - 7.104 mg; glycerol 85% (weight / mass) - 0.205 mg; titanium dioxide (E171, C.1.77891) - 0.411 mg; indigo carmine (E132, C.1.73015) - 0.051 mg; wax montaglycol - 0.075 mg

pharmachologic effect

The pharmacological action is estrogenic.

It replenishes the insufficient production of endogenous estrogens, lowers the level of LDL cholesterol in the blood. It relieves somatic, mental and other climacteric symptoms during pre- and postmenopausal periods or after ovariectomy; prevents bone mass reduction and osteoporosis.

Indications

Estrogen deficiency (postmenopausal period, ovariectomy, radiation castration), accompanied by vasomotor symptoms: hot flushes, sweating, sleep disturbances, depressive states, irritability, headache, dizziness, bladder hyperesthesia, degenerative changes in the skin and mucous membranes; prevention of osteoporosis.

Contraindications

Hypersensitivity, pregnancy, breast-feeding, severe liver dysfunction, Dubin-Johnson and Rotor syndromes, liver tumors and thromboembolic processes (including in the anamnesis), breast cancer, existing or suspected tumors sensitive to sex steroid hormones, severe hypertriglyceridemia, vaginal bleeding of unknown origin.

pregnancy and lactation

Contraindicated in pregnancy. For the duration of treatment, breastfeeding should be discontinued.

Side effects

In rare cases - headache, nausea, gastric dysfunction, breast engorgement, weight change, uterine bleeding, chloasma.

Dosing and Administration

Inside, after eating, without chewing and washing down with a small amount of liquid, 1 pills daily for 21 days, then - a break of 7 days.

In the presence of menstruation should take Proginova on the 5th day of menstrual bleeding.

In any other case, immediate treatment recommended by a doctor is possible.

With the preservation of the uterus, additional prescription of another hormone, progesterone, is possible. And a doctor's recommendation is necessary: should the dragees be taken continuously (without interruptions) or with interruptions.

The time of the day of taking Proginov does not matter. However, if the first pills are taken at a certain time of the day, you should adhere to this time and when taking all the subsequent pills.

Form of issue

Dragee, 2 mg. In the blister is 21 pcs .; in a pack of cardboard 1 blister.

Conditions of leave from pharmacies

On prescription.

Storage conditions for Proginova®

At a temperature not exceeding 30 ° C.

Keep out of the reach of children.

Shelf life of Proginova®

5 years.

Do not use after the expiry date printed on the package.